BIOLIFE SOLUTIONS INC (BLFS): Completion of Acquisition or Disposition of Assets

BIOLIFE SOLUTIONS INC (BLFS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 2.01 Completion of Acquisition or Disposition of Assets. The information set forth in the “Explanatory Note” of this Current Report on Form 8-K is incorporated by reference into this Item 2.01. At the effective time of the First Merger (the “First Merger Effective Time”), ea

Event · M&A · completed
Role
target
Counterparty
Repligen Corporation
Consideration
mixed
Price per share
$11.25 in cash
Also in this documentListing notice · delistingExec change · resigned

Facts are quoted from the filing text and checked against it.

Original reporting
Published Oct 6, 2026, 1:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 1:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$BLFS
Neutral
high confidence
Mentioned
$BLFS · $RGEN
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$BLFSNeutralHigh
01

Why it matters

The filing provides definitive terms of the merger, enabling investors to act on the imminent cessation of BLFS trading and the receipt of RGEN shares and cash.

02

Market read

Immediate trading impact for BLFS shareholders and potential price movement for RGEN.

03

What to watch

Potential tax implications for BLFS shareholders and the exact cash payout timing could affect net proceeds.

Relevance 7/10Novelty 8/10Timing: effective October 6, 2026 (pre‑market)

Background

BioLife Solutions announced completion of its merger with Repligen, resulting in delisting from Nasdaq and conversion of shares.

Company-level read

Ticker impact

$BLFSNeutralHigh confidence
Context

SEC 8‑K reports completion of BioLife Solutions merger, delisting and conversion of shares into Repligen stock and cash.

Expected impact

downward pressure on BLFS as it delists, positive impact on RGEN from new shareholders receiving stock.

Evidence & confidence

The merger is final, trading will be halted and the company will be deregistered, forcing investors to adjust positions immediately.

$RGENBullishHigh confidence
Context

Repligen is the acquiring company, issuing 0.1442 shares per BioLife share as part of the merger consideration.

Expected impact

likely modest upside as market prices in the new equity infusion and cash consideration.

Evidence & confidence

The transaction adds equity holders and cash, which is generally viewed favorably for the acquirer.

Market effects

Consolidation in the biotech services sector; may prompt re‑evaluation of peer valuations.

U.S. biotech market sees a minor shift as a small‑cap merges and delists.

Limited to investors holding BLFS or RGEN; no broader macro impact.

Counterpoint

Some investors may view the cash component as a red flag, preferring to short RGEN anticipating dilution.

Key entities

  • BioLife Solutions Inc.

    Target company being merged and delisted.

  • Repligen Corp.

    Acquiring company issuing stock as consideration.

Related articles

$RGENMed

Stifel reiterates Buy on Repligen stock, keeps $207 target

Stifel maintained a Buy rating on Repligen (NASDAQ:RGEN) with a $207 price target, citing upside from the Biolife acquisition and strong 2027 outlook. The stock has risen 51% in six months. Repligen reported Q3 2026 earnings of $0.53 per share, beating estimates, with revenue up 11% YoY. Canaccord Genuity kept a Hold rating with a $180 target.

$RGENHighAI 8/10

RGEN Q3 deep dive: margin headwinds and BioLife integration shape improved full-year outlook

Repligen reported Q3 revenue of $209.3M, beating estimates, with adjusted EPS of $0.53 and adjusted EBITDA of $43.84M. The company raised full-year revenue guidance to $848M and adjusted EPS to $2.07. Growth was driven by proteins and chromatography segments, while filtration revenue declined. The BioLife acquisition is expected to drive future growth and margin expansion.

$RGENMed

Repligen Announces $1 Bln Convertible Notes Offering To Extend Debt Maturity

Repligen Corp. (RGEN) announced a $1 billion convertible notes offering due 2031. $541.4 million will exchange existing 2028 notes, while $458.6 million will be issued for cash. The new notes have a 20% premium conversion price. Proceeds will fund share repurchases, working capital, and potential acquisitions. The deal extends debt maturity and reduces interest expenses, benefiting EPS from 2026.